New Tactic In ANDA Litigation: Novo Blocks Generic Prandin By Changing Its Patent Use Code

Novo Nordisk succeeded in an unusual maneuver in blocking Caraco Pharmaceutical from getting a generic version of its blood glucose-lowering drug Prandin (repaglinide) on the market. It changed the use code on the patent covering the drug in combination with metformin so that Caraco could not get approval for a monotherapy